Literature DB >> 19437129

Large neutral amino acids supplementation in phenylketonuric patients.

J C Rocha1, F Martel.   

Abstract

Phenylketonuria is an inborn error of amino acid metabolism that results in severe mental retardation if not treated early and appropriately. The traditional treatment, consisting of a low-phenylalanine diet, is usually difficult to maintain throughout adolescence and adulthood, resulting in undesirable levels of blood phenylalanine and consequent neurotoxicity. The neurotoxicity of phenylalanine is enhanced by its transport mechanism across the blood-brain barrier, which has the highest affinity for phenylalanine compared with the other large neutral amino acids that share the same carrier. The supplementation of large neutral amino acids in phenylketonuric patients has been showing interesting results. Plasma phenylalanine levels can be reduced, which may guarantee important metabolic and clinical benefits to these patients. Although long-term studies are needed to determine the efficacy and safety of large neutral amino acids supplements, the present state of knowledge seems to recommend their prescription to all phenylketonuric adult patients who are non-compliant with the low-phenylalanine diet.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437129     DOI: 10.1007/s10545-009-1132-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  72 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Na+ -dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal.

Authors:  Robyn L O'Kane; Juan R Viña; Ian Simpson; Richard A Hawkins
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-05-27       Impact factor: 4.310

Review 3.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

4.  Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.

Authors:  Harvey Levy; Barbara Burton; Stephen Cederbaum; Charles Scriver
Journal:  Mol Genet Metab       Date:  2007-12       Impact factor: 4.797

5.  Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

6.  Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis.

Authors:  Marieke Hoeksma; Dirk-Jan Reijngoud; Jan Pruim; Harold W de Valk; Anne M J Paans; Francjan J van Spronsen
Journal:  Mol Genet Metab       Date:  2009-02-06       Impact factor: 4.797

7.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

8.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

9.  Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

Authors:  F Güttler; H Lou
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

10.  Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy.

Authors:  R Kreis; J Pietz; J Penzien; N Herschkowitz; C Boesch
Journal:  J Magn Reson B       Date:  1995-06
View more
  13 in total

Review 1.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

2.  Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.

Authors:  Burcu Kumru; Davut Sinan Kaplan; Burcu Oztürk Hismi; Hakim Celik
Journal:  Cell Mol Neurobiol       Date:  2017-12-28       Impact factor: 5.046

Review 3.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites.

Authors:  Renaud Schoemans; Marie-Stéphane Aigrot; Chaohong Wu; Raphaël Marée; Pengyu Hong; Shibeshi Belachew; Claire Josse; Catherine Lubetzki; Vincent Bours
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

5.  Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation.

Authors:  Jytte Bieber Nielsen; Karin E Nielsen; Flemming Güttler
Journal:  J Inherit Metab Dis       Date:  2010-02       Impact factor: 4.982

6.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

7.  Protein substitutes for phenylketonuria in Europe: access and nutritional composition.

Authors:  M J Pena; M F de Almeida; E van Dam; K Ahring; A Bélanger-Quintana; K Dokoupil; H Gokmen-Ozel; A M Lammardo; A MacDonald; M Robert; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2016-04-27       Impact factor: 4.016

Review 8.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

Review 9.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10

Review 10.  Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders.

Authors:  Karolina M Stepien; Robert Heaton; Scott Rankin; Alex Murphy; James Bentley; Darren Sexton; Iain P Hargreaves
Journal:  J Clin Med       Date:  2017-07-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.